Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2025-01-24 Capital/Financing Update
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2025
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares of common stock issuable upon conversion of senior secured convertible notes and exercise of warrants. It includes extensive information about the offering, risk factors, management discussion and analysis, executive compensation, beneficial ownership, and other corporate details. The document is not a financial report, earnings release, or regulatory filing in the typical sense but rather a capital markets document related to financing and securities offering. The presence of terms like 'prospectus,' 'registration statement,' and detailed offering terms indicates this is a Capital/Financing Update filing. The document length and content confirm it is not a brief announcement or a report publication announcement but a full prospectus related to capital raising activities.
2025-01-24 English
Regulatory Filings 2025
Regulatory Filings
2025-01-24 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting withdrawal of a Registration Statement on Form S-1. It references Rule 477 under the Securities Act of 1933 and states that the registration statement is not effective and no securities have been issued. The document is a formal regulatory communication about the withdrawal of a filing, not a financial report or announcement of financial results. The document length is short (1658 characters) and it is clearly a regulatory filing related to securities registration withdrawal. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related filing that does not fit other categories.
2025-01-22 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from Shuttle Pharmaceuticals Holdings, Inc. to the SEC requesting acceleration of the effective date of a registration statement on Form S-1. It is a formal communication related to the registration process for securities, specifically a request under Rule 461 of the Securities Act. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but is not itself a capital/financing update or a registration statement filing. Given the short length (1454 characters) and the nature of the content as a formal request to the SEC, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2025-01-21 English
Regulatory Filings 2025
Regulatory Filings
2025-01-21 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes a press release about the enrollment progress in a Phase 2 clinical trial by Shuttle Pharmaceuticals Holdings, Inc. It includes no financial statements or detailed financial analysis but rather an update on a clinical trial event. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. This type of filing is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Annual Report, Earnings Release, or Management Reports. The document length (7029 characters) and content confirm it is not a brief announcement of a report publication but a standalone regulatory filing.
2025-01-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.